

SUPPLEMENTAL DATA

Table 1. Schedule of study procedures for the target and source populations		
Procedures	Target population	Source population
	Throughout the study period	Within 30 days prior to surgery
Verify eligibility criteria	X	
Collection of anonymized surveillance data	X	
Written informed consent		X ^a
Nasal swab for <i>S. aureus</i> colonization status		X ^{b,c,e}
Throat swab for <i>S. aureus</i> colonization status		X ^{b,c,e}
Perineal swab for <i>S. aureus</i> colonization status		X ^{b,c,e}
Preoperative blood sample (serum)		X ^d
Assignment of SID number		X
Collection of data from medical chart		X

^a For emergency surgeries, IC may be obtained up to 72 hours after the surgery.

^b Semi-quantitative testing on provided chromogenic media to occur at the local laboratory.

^c *S. aureus* strains will be prepared in microbanks by the local laboratory and shipped to the central laboratory.

^d Aliquots will be prepared in the local laboratory and shipped to the central laboratory. Testing to occur at a central laboratory.

^e Every attempt should be made to collect all 3 preoperative screening swabs from subjects undergoing emergency surgery. If all 3 samples cannot be collected, a nose swab AND throat OR perineal swab must be collected.

Table 2. Schedule of study procedures for study cohort population						
Procedures	Study cohort population				In case of a SSI	
	< 72 hours after the surgery	Across hospital stay until discharge	Hospital discharge	Post-discharge follow-up	Day of SSI diagnosis	Day 28 +/- 14 after SSI diagnosis
				Day 7, day 14, day 21, day 28, day 60 and day 90 (+/- 3 days each)		
Enrollment in the study cohort	X ^a					
Collection of additional data from the medical chart		X		X		
Assessment of post-surgical infectious status		X ^b		X ^b		
Assessment of post-surgical mortality status			X	X		
Surgical site sample					X ^c	
Post-SSI blood sample (serum)						X ^d

^a Only if the subject is *S. aureus* colonized (then always include), or non-colonized, but is preceded by (at least) 2 enrolled *S. aureus* colonized subjects.

^b Microbanks of *S. aureus* strains cultured from routine clinical microbiological samples (samples taken for medical care purposes) will be prepared by the local laboratory and shipped to the central laboratory.

^c Testing to occur at the local laboratory. If *S. aureus* is found, microbanks of the infecting *S. aureus* strains will be prepared and shipped to the central laboratory.

^d Collection will occur only if available, e.g. if a routine postoperative visit is planned at the moment that the sample should be collected. Aliquots will be prepared in the local laboratory and shipped to the central laboratory for testing.

STUDY OBJECTIVES

Primary Objective

1. To assess the incidence of ***S. aureus* SSI** (composite of superficial, deep, and organ/space *S. aureus* SSI) up to 90 days following surgery and its independent association with patient-related, pathogen-related and contextual factors.

Secondary Objectives

1. To develop risk prediction models to quantify the risk of acquiring a *S. aureus* SSI and *S. aureus* bloodstream infection (BSI) up to 90 days following surgery, by using a composite score of independent risk factors identified through the primary objective.
2. To assess the incidence of **serious *S. aureus* SSI** (deep and organ/space *S. aureus* SSI) up to 90 days following surgery and its independent association with patient-related, pathogen-related and contextual factors.
3. To assess the incidence of ***S. aureus* BSI** up to 90 days following surgery and its independent association with patient-related, pathogen-related and contextual factors.
4. To assess the incidence of **other post-surgical *S. aureus* infections** up to 90 days following surgery.
5. To assess the incidence of **all-cause SSI**, by etiologic agent, and to describe its temporal distribution up to 90 days following surgery.
6. To assess the incidence of ***S. aureus* SSI stratified by antibiotic susceptibility** (e.g. methicillin-susceptible *S. aureus* (MSSA) versus methicillin-resistant *S. aureus* (MRSA)).
7. To compare the prevalence of preoperative *S. aureus* colonization in the nose, throat, and perineal region.
8. To assess the incidence of ***S. aureus* SSI stratified by location of preoperative *S. aureus* colonization.**
9. To assess the colonizing bacterial load of *S. aureus* in the nose, throat, and perineal region semi-quantitatively, and its independent association with *S. aureus* infection up to 90 days following surgery.
10. To assess the incidence of **postsurgical all-cause mortality** up to 90 days following surgery and its independent association with patient-related and contextual factors.
11. To characterize the *S. aureus* isolates involved in *S. aureus* colonization and infection.
12. To explore the role of antibodies against *S. aureus* virulence factors as potential biomarkers associated with *S. aureus* infection.
13. To compare the study cohort population against the target population.

Exploratory Objectives

1. To describe the magnitude of healthcare utilization associated with *S. aureus* SSI in terms of:
 - a. Length of stay (LOS) after the index surgery.
 - b. Incidence of readmissions, including re-interventions.
 - c. LOS during readmissions
2. To assess the incidence of ***S. aureus* SSI stratified by participating country.**
3. To assess the incidence of ***S. aureus* SSI stratified by type of surgery.**
4. To assess the incidence of ***S. aureus* SSI stratified by wound classification.**
5. To assess the incidence of ***S. aureus* SSI stratified by the urgency of surgery.**
6. To assess the incidence of ***S. aureus* SSI stratified by American Society of Anesthesiologists physical status (ASA PS) classification.**
7. To assess the risk prediction model derived in Work Package 6A stage 1.

STUDY OUTCOMES

Primary study outcome

1. Incidence of *S. aureus* SSI up to 90 days following surgery.

Secondary study outcomes

1. Time to *S. aureus* SSI (superficial, deep, and organ-space *S. aureus* SSI) up to 90 days following surgery.
2. Incidence of **serious *S. aureus* SSI** (deep and organ/space *S. aureus* SSI) up to 90 days following surgery.
3. Incidence of *S. aureus* BSI up to 90 days following surgery.
4. Time to *S. aureus* BSI up to 90 days following surgery.
5. Incidence of **other post-surgical *S. aureus* infection** up to 90 days following surgery.
6. Time to **other post-surgical *S. aureus* infection** up to 90 days following surgery.
7. Incidence of **all-cause SSI**, by etiologic agent, up to 90 days following surgery.
8. Time to **all-cause SSI** up to 90 days following surgery.
9. Incidence of *S. aureus* SSI **stratified by antibiotic susceptibility** (e.g. MSSA vs. MRSA).
10. Prevalence of preoperative *S. aureus* colonization in nose, throat and perineal region.
11. Incidence of *S. aureus* SSI **stratified by location of preoperative *S. aureus* colonization**.
12. Semi-quantification of the bacterial load of colonizing *S. aureus*.
13. Incidence of **post-surgical all-cause mortality** up to 90 days following surgery.
14. Time to **post-surgical death of all causes** up to 90 days following surgery.
15. Clonal type, gene sequence, and expression of certain virulence factors of *S. aureus* isolates involved in colonization and infection.
16. Serum antibody levels against *S. aureus* virulence factors.

Exploratory outcomes

1. Magnitude of healthcare utilization associated with *S. aureus* SSI up to 90 days following surgery in terms of:
 - a. Duration of LOS
 - b. Incidence of readmissions, including re-interventions due to *S. aureus* SSI up to 90 days following surgery.
 - c. Duration of LOS during readmissions.
2. Incidence of *S. aureus* SSI up to 90 days following surgery, **stratified by participating country**.
3. Incidence of *S. aureus* SSI up to 90 days following surgery, **stratified by type of surgery**.
4. Incidence of *S. aureus* SSI up to 90 days following surgery, **stratified by wound classification**.

5. Incidence of *S. aureus* SSI up to 90 days following surgery, **stratified by urgency of surgery.**
6. Incidence of *S. aureus* SSI up to 90 days following surgery, **stratified by ASA PS-classification.**
7. Risk assessment of the risk prediction model derived in Work Package 6A stage 1.